Natera, Inc. (NASDAQ:NTRA) Insider John Fesko Sells 669 Shares

Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider John Fesko sold 669 shares of the stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $159.60, for a total value of $106,772.40. Following the completion of the sale, the insider now directly owns 114,142 shares in the company, valued at $18,217,063.20. This represents a 0.58 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Natera Stock Down 1.7 %

Shares of Natera stock traded down $2.75 on Thursday, hitting $159.64. 519,178 shares of the company traded hands, compared to its average volume of 1,329,178. The company has a market cap of $21.08 billion, a PE ratio of -90.70 and a beta of 1.63. The company has a 50-day moving average price of $149.42 and a 200 day moving average price of $127.56. Natera, Inc. has a 12-month low of $58.53 and a 12-month high of $175.63. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.31. The business had revenue of $439.80 million during the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. Natera's quarterly revenue was up 63.9% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.95) EPS. Sell-side analysts predict that Natera, Inc. will post -1.61 earnings per share for the current year.

Hedge Funds Weigh In On Natera

A number of hedge funds have recently modified their holdings of NTRA. Itau Unibanco Holding S.A. bought a new stake in Natera during the 2nd quarter worth approximately $28,000. Quarry LP boosted its position in shares of Natera by 148.4% in the 2nd quarter. Quarry LP now owns 318 shares of the medical research company's stock worth $34,000 after purchasing an additional 190 shares during the last quarter. Covestor Ltd grew its position in shares of Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company's stock worth $47,000 after buying an additional 95 shares during the period. GAMMA Investing LLC raised its holdings in Natera by 32.7% in the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company's stock worth $55,000 after purchasing an additional 106 shares during the period. Finally, True Wealth Design LLC acquired a new position in Natera in the third quarter valued at about $57,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Craig Hallum boosted their price target on shares of Natera from $121.00 to $157.00 and gave the company a "buy" rating in a research report on Wednesday, November 13th. StockNews.com lowered shares of Natera from a "hold" rating to a "sell" rating in a research note on Thursday, November 14th. Robert W. Baird boosted their target price on shares of Natera from $120.00 to $160.00 and gave the stock an "outperform" rating in a research report on Wednesday, November 13th. Piper Sandler raised their price objective on Natera from $150.00 to $200.00 and gave the company an "overweight" rating in a research note on Monday, November 18th. Finally, Sanford C. Bernstein lifted their target price on shares of Natera from $125.00 to $135.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $152.67.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.